Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer
American Society of Clinical OncologyPublished: May 20, 2024
- Key Points
- New Recommendations from 2024
- Treatment Recommendations
- Use of an Anthracycline-Taxane Regimen
- Optimal-Dose Anthracycline Regimen for Patients for Whom a Taxane Is Contraindicated
- Adding Gemcitabine or Capecitabine to an Anthracycline-Taxane Regimen
- Capecitabine in Patients Age ≥65 Years
- Cyclophosphamide-Methotrexate-Fluorouracil As an Alternative To Doxorubicin-Cyclophosphamide
- Acceptable Adjuvant Chemotherapy Regimens for Patients with Higher-Risk Early Breast Cancer
- Adjuvant Regimen When an Anthracycline Is Not Preferred
- Patient Selection and Adjuvant Trastuzumab Therapy
- Trastuzumab Plus Chemotherapy in Patients with Higher-Risk Her2-Positive Disease
- Trastuzumab Plus Chemotherapy in Patients with Her2-Positive T1a-B N0 Disease
- Selection of Chemotherapy Regimens in Patients Receiving Trastuzumab
- Use of Trastuzumab and an Anthracycline-Containing Regimen
- Concurrent Administration of Adjuvant Trastuzumab and Non-Anthracycline Chemotherapy Regimens
- Trastuzumab-Based Chemotherapy or Trastuzumab Regimens For Patients at Higher Risk of Cardiotoxicity
- Addition of Trastuzumab to Chemotherapy Regimens Not Evaluated in a Phase III Trial
- Duration of Trastuzumab Therapy and Cardiac Function
- Adjuvant Capecitabine
- Adjuvant Pertuzumab
- Adjuvant Neratinib
- Adjuvant Abemaciclib
Also Found In
You rely on Guideline Central for transparency
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.